The Effects of αvβ3 Integrin Blockage in Breast Tumor and Endothelial Cells Under Hypoxia In Vitro
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Breast cancer is characterized by a hypoxic microenvironment inside the tumor mass, contributing to cell metastatic behavior. Hypoxia induces the expression of hypoxia-inducible factor (HIF-1α), a transcription factor for genes involved in angiogenesis and metastatic behavior, including the vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), and integrins. Integrin receptors play a key role in cell adhesion and migration, being considered targets for metastasis prevention. We investigated the migratory behavior of hypoxia-cultured triple-negative breast cancer cells (TNBC) and endothelial cells (HUVEC) upon αvβ3 integrin blocking with Dis-01, an RGD disintegrin with high affinity to this integrin. Boyden chamber, HUVEC transmigration, and wound healing assays in the presence of Dis-01 were performed in hypoxic conditions. Dis-01 produced similar effects in the two oxygen conditions in the Boyden chamber and transmigration assays. In the wound healing assay, hypoxia abolished Dis-01's inhibitory effect on cell motility and decreased the MMP-9 activity of conditioned media. These results indicate that αvβ3 integrin function in cell motility depends on the assay and oxygen levels, and higher inhibitor concentrations may be necessary to achieve the same inhibitory effect as in normoxia. These versatile responses add more complexity to the role of the αvβ3 integrin during tumor progression.
Kostryukova L, Serdyukova A, Pronina V, Shumyantseva V, Tereshkina Y Pharmaceutics. 2024; 16(11).
PMID: 39598535 PMC: 11597883. DOI: 10.3390/pharmaceutics16111412.
Serum Extracellular Vesicles Cargo Approach in Bitches with Mammary Tumors.
Sousa G, Carvalho M, Fonseca-Alves C, Souza F Curr Issues Mol Biol. 2024; 46(7):7745-7768.
PMID: 39057100 PMC: 11275879. DOI: 10.3390/cimb46070459.
The potential and promise for clinical application of adoptive T cell therapy in cancer.
Li Y, Zheng Y, Liu T, Liao C, Shen G, He Z J Transl Med. 2024; 22(1):413.
PMID: 38693513 PMC: 11064426. DOI: 10.1186/s12967-024-05206-7.
Casali B, Baptista M, Pachane B, Cortez A, Altei W, Selistre-de-Araujo H Biochem Biophys Rep. 2024; 38:101686.
PMID: 38524278 PMC: 10957371. DOI: 10.1016/j.bbrep.2024.101686.
Benedetti A, Turco C, Gallo E, Daralioti T, Sacconi A, Pulito C Cell Death Dis. 2024; 15(2):113.
PMID: 38321003 PMC: 10847507. DOI: 10.1038/s41419-024-06491-2.